Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Sep 29, 2018 in Colorectal cancer | 0 comments

In a nutshell

This study compared the effectiveness of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) with other treatment options in patients with colorectal cancer (CRC) and peritoneal metastasis (PM; when cancer spreads to the abdominal lining). Researchers suggested that CRS + HIPEC brings the greatest benefit to these patients.

Some background

PM affects around 10% of patients with CRC and is associated with poor outcomes. This is true even when these patients are treated with modern chemotherapy. Survival improvements have been reported with CRS and HIPEC. CRS involves the surgical removal of tumors from the abdominal lining. HIPEC is a heated, highly concentrated chemotherapy that is delivered directly to the abdomen during CRS. The effectiveness of CRS combined with HIPEC compared to other treatment options to treat PM in patients with CRC is not clear. 

Methods & findings

This study included information about 370 patients with CRC and PM. Patients were divided into 5 different groups. Group A received CRS and HIPEC (7.6% of patients), group B received surgery and chemotherapy (22.1%), group C received chemotherapy only (36.2%), group D received surgery only (12.2%) and group E received best supportive care (treatment of symptoms only (21.9%).

The average overall survival (OS; total time patients were alive after treatment) was the highest for patients in group A (41.6 months). Patients from group B had an OS of 24 months. Group C had an OS of 14.1 months, group D of 11.4 months and group E of 7.9 months.

Compared to group E, patients in group A had an 81% higher chance of survival. Group B had a 60% higher survival and groups C and D had a 43 and a 42 higher survival than group E.

The bottom line

This study reported that patients with colorectal cancer and peritoneal metastasis would significantly benefit from cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy

The fine print

This was a retrospective study. It means the authors looked back in time to analyze data.

Published By :

International Journal of Colorectal Disease

Date :

Aug 21, 2018

Original Title :

Benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with isolated peritoneal metastases from colorectal cancer.

click here to get personalized updates